A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
Phase of Trial: Phase I/II
Latest Information Update: 19 Oct 2017
At a glance
- Drugs WX 554 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Heidelberg Pharma AG
- 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
- 28 Sep 2016 Results of this trial, published in the European Journal of Cancer.
- 14 Apr 2014 Status changed from recruiting to discontinued, as reported in a Wilex media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History